Compare CAE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAE | LEGN |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | CAE | LEGN |
|---|---|---|
| Price | $29.71 | $22.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $33.75 | ★ $69.67 |
| AVG Volume (30 Days) | 570.3K | ★ 2.5M |
| Earning Date | 11-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $3,470,482,234.00 | $909,045,000.00 |
| Revenue This Year | $6.40 | $68.83 |
| Revenue Next Year | $5.69 | $51.27 |
| P/E Ratio | $30.62 | ★ N/A |
| Revenue Growth | 9.12 | ★ 74.75 |
| 52 Week Low | $20.36 | $22.28 |
| 52 Week High | $30.13 | $45.30 |
| Indicator | CAE | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 76.89 | 21.96 |
| Support Level | $27.07 | $26.43 |
| Resistance Level | $28.58 | $28.97 |
| Average True Range (ATR) | 0.65 | 1.57 |
| MACD | 0.35 | -0.43 |
| Stochastic Oscillator | 99.41 | 0.91 |
CAE Inc provides training and aviation services, integrated enterprise solutions, in-service support, and crew-sourcing services. The company operations are managed through two segments: Civil Aviation which offers comprehensive training solutions for flight, cabin, maintenance, and ground personnel in commercial, business, and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training, and crew sourcing services, as well as aircraft flight operations solutions; and Defense and Security which is a world-wide training and simulation provider delivering scalable, platform-independent solutions that enable and enhance force readiness and security. It generates the majority of its revenue from the Civil Aviation segment.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.